January 8, 2018
The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.
March 6, 2017
Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials.
February 21, 2017
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
February 3, 2015
ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment.
January 28, 2015
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.